ABBN.SW: $86.50 ▲ 0.40 (0.46%)ASML.AS: $1,578.40 ▲ 17.60 (1.13%)ENR.DE: $160.60 ▼ -1.90 (-1.17%)GLEN.L: $532.40 ▼ -2.90 (-0.54%)IFX.DE: $81.31 ▲ 0.75 (0.93%)NOKIA.HE: $12.36 ▲ 0.36 (3.00%)RIO.L: $7,258.00 ▼ -6.00 (-0.08%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Bionano Genomics, Inc.

BNGO - NASDAQ

Identifiants & Marche

Ticker BNGO
ISIN US09075F3055
CIK 0001411690
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.